VERSANT HCV Genotype 2.0 Assay (LiPA)
Performance to Meet Your Needs
The VERSANT HCV Genotype 2.0 Assay is a Line Probe Assay (LiPA) that utilizes the trusted reverse-hybridization technology to detect genotypes 1-6 and subtypes 1a vs. 1b, and subtypes 6 (c-I) all while decreasing the number of undetermined subtype results. With this assay, your lab can identify more than 15 different subtypes while taking note of rare patterns that are contained in the updated interpretation chart. The VERSANT HCV Genotype 2.0 Assay is the most widely used HCV genotyping assay.
This product is intended to be used to guide the selection of treatment type and duration for individuals being considered for antiviral treatment who are chronically infected with HCV. Thus, the assay is intended to be used with samples known to be positive for HCV RNA. The VERSANT HCV Genotype 2.0 Assay (LiPA) is not intended to be used as a screening test for HCV or as a diagnostic test to confirm the presence of HCV.
The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.